Vetoquinol SA (FRA:8JM)

Market Cap	857.55M
Revenue (ttm)	532.39M
Net Income (ttm)	59.96M
Shares Out	n/a
EPS (ttm)	5.10
PE Ratio	14.30
Forward PE	14.18
Dividend	0.89 (1.22%)
Ex-Dividend Date	Jun 4, 2025

Volume	1
Average Volume	1
Open	71.60
Previous Close	70.70
Day's Range	71.60 - 73.20
52-Week Range	63.10 - 83.40
Beta	n/a
RSI	52.80
Earnings Date	Mar 20, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 2,501
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8JM

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.